Syndax Pharmaceuticals (SNDX) Operating Expenses (2015 - 2026)

Syndax Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $99.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 4.56% year-over-year to $99.1 million in Q1 2026; TTM through Mar 2026 was $441.0 million, a 13.75% increase from a year earlier, with the FY2025 full-year figure at $445.4 million, up 22.59% from the prior year.
• Operating Expenses fell to $99.1 million in Q1 2026 per SNDX's latest filing, from $131.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $131.3 million in Q4 2025 and bottomed at $35.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $77.9 million (2023), against an average of $75.9 million.
• Across the five-year window, Operating Expenses surged 85.34% in 2023 and retreated 4.56% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $42.0 million in 2022, then jumped by 85.34% to $77.9 million in 2023, then jumped by 33.55% to $104.0 million in 2024, then advanced by 26.17% to $131.3 million in 2025, then dropped by 24.54% to $99.1 million in 2026.
• Per Business Quant, the three latest SNDX Operating Expenses figures stand at $99.1 million (Q1 2026), $131.3 million (Q4 2025), and $103.3 million (Q3 2025).